STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] BIOTRICITY INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Ionic Ventures, LLC, Ionic Management, LLC, Brendan O’Neil, and Keith Coulston filed a Schedule 13G/A (Amendment No. 5) disclosing beneficial ownership of 2,926,171 shares of Biotricity Inc. (BTCY), representing 9.9% of the class, based on 26,567,769 shares outstanding as of August 13, 2025.

The position comprises 202,937 common shares and up to 2,723,234 shares issuable upon conversion of Series B Convertible Preferred Stock, subject to a 9.99% beneficial ownership limitation in the Certificate of Designations. As of September 30, 2025, up to 4,245,283 shares could be issuable within sixty days at an Alternate Conversion Price of $0.53, though portions are not deemed beneficially owned due to blocker and conversion notice limits. The reporting persons have shared voting and dispositive power over 2,926,171 shares and no sole power. They certify the holdings are not for the purpose of changing or influencing control.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 5 to Statement on Schedule 13G (this ''Amendment No. 5''), such shares and percentage are based on 26,567,769 shares of the issuer's common stock, par value $0.001 per share (the ''Common Stock''), outstanding as of August 13, 2025, as disclosed in the issuer's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed by the issuer with the U.S. Securities and Exchange Commission (the ''SEC'') on August 14, 2025 (the ''Form 10-Q''). Ownership consists of (i) 202,937 shares of Common Stock held by the reporting person and (ii) an aggregate of up to 2,723,234 shares of Common Stock (the ''Conversion Shares'') issuable upon conversion of shares of Series B Convertible Preferred Stock, par value $0.001 per share, of the issuer (the ''Preferred Stock'') directly held by the reporting person, further conversions of which are subject to a 9.99% beneficial ownership limitation provision (the ''Blocker'') contained in the issuer's Amended Certificate of Designations of the Preferred Stock (the ''Certificate of Designations'').


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 5, such shares and percentage are based on 26,567,769 shares of Common Stock outstanding on August 13, 2025, as disclosed in the Form 10-Q. Ownership consists of (i) 202,937 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,723,234 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the 9.99% Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 5, such shares and percentage are based on 26,567,769 shares of Common Stock outstanding on August 13, 2025, as disclosed in the Form 10-Q. Ownership consists of (i) 202,937 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,723,234 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the 9.99% Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 5, such shares and percentage are based on 26,567,769 shares of Common Stock outstanding on August 13, 2025, as disclosed in the Form 10-Q. Ownership consists of (i) 202,937 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,723,234 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the 9.99% Blocker contained in the Certificate of Designations.


SCHEDULE 13G



Ionic Ventures, LLC
Signature:/s/ Ionic Ventures, LLC
Name/Title:Keith Coulston, Manager of Ionic Management, LLC, Manager of Ionic Ventures, LLC
Date:11/14/2025
Ionic Management, LLC
Signature:/s/ Ionic Management, LLC
Name/Title:Keith Coulston, Manager
Date:11/14/2025
Brendan O'Neil
Signature:/s/ Brendan O'Neil
Name/Title:Brendan O'Neil
Date:11/14/2025
Keith Coulston
Signature:/s/ Keith Coulston
Name/Title:Keith Coulston
Date:11/14/2025

Comments accompanying signature: LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated August 8, 2024 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on August 8, 2024).

FAQ

What stake did Ionic report in Biotricity (BTCY)?

They reported beneficial ownership of 2,926,171 shares, equal to 9.9% of Biotricity’s common stock.

How was the 9.9% ownership calculated for BTCY?

It is based on 26,567,769 shares outstanding as of August 13, 2025, as disclosed in Biotricity’s Form 10-Q.

What securities make up Ionic’s BTCY position?

It includes 202,937 common shares and up to 2,723,234 shares issuable upon conversion of Series B Convertible Preferred Stock.

What is the beneficial ownership limitation mentioned?

A 9.99% blocker in the Certificate of Designations limits conversions that would push ownership above 9.99%.

What are the voting and dispositive powers over the BTCY shares?

The reporting persons have shared voting and dispositive power over 2,926,171 shares and no sole power.

What conversion terms are referenced in the filing?

Within sixty days of September 30, 2025, up to 4,245,283 shares could be issuable at an Alternate Conversion Price of $0.53, subject to blocker and conversion notice limits.

Did the reporting persons state an intent to influence control of BTCY?

They certified the securities were not acquired or held for the purpose of changing or influencing control.
Biotricity Inc

OTC:BTCY

BTCY Rankings

BTCY Latest News

BTCY Latest SEC Filings

BTCY Stock Data

14.29M
16.12M
39.37%
1.86%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY